glp 1 drug made by eli lilly to seek approval of new GLP-1 weight-loss this year Best Weight Loss Drug Stocks
Description
They are also seen as a key expansion direction for obesity and metabolic disease therapies
Tirzepatide users were less likely to experience any major cardiovascular problems following surgery than people not on the drug (roughly 30% lower risk), though the rate of some problems like heart attacks remained roughly the same between the two groups
That number is up from 22% in Q1 2024
Cardiovascular and Metabolic Health Semaglutide has the stronger long-term cardiovascular outcome data , showing reduced risk of major adverse cardiovascular events in high-risk patients with type 2 diabetes
